Reader Comments

The CD-47 targeting therapeutics market

by james hebrew (2022-04-25)

In response to world

Upon realizing the potential of this novel target, industry stakeholders have initiated several R&D efforts focused on exploiting the use of CD47 as an effective biomarker for the diagnosis and treatment purposes.

Roots Analysis has announced the addition of “CD-47 Therapeutics Market, 2021-2035” report to its list of offerings.

In recent years, the focus of the research community has shifted towards the development of novel treatment modalities, such as T- cell immunotherapies, that exhibit high efficacy. CD-47, owing to its increased expression on the surface of cancer cells, has emerged as a cancer immune checkpoint biomarker.

To order this 190+ page report, which features 142+ figures, please visit

Critical Literacy: Theories and Practices is a non-commercial initiative committed to the ethical dissemination of academic research and educational thinking. CLTP acknowledges the thoughtful dedication of authors, editors and reviewers to develop and promote this open journal initiative. The journal receives copy-editing sponsorship from the Faculty of Education at the University of Oulu, Finland. CLTP has previously received  copy editing support from the Centre for the Study of Social and Global Justice at the University of Nottingham, UK.